Your browser doesn't support javascript.
loading
U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario.
Bracarda, Sergio; Iacovelli, Roberto; Baldazzi, Valentina; Zucali, Paolo Andrea; Gernone, Angela; Conti, Giario Natale; Pappagallo, Giovanni; Brunelli, Matteo; Bruzzi, Paolo; Fiorini, Edoardo; Magenta, Laura; Diomede, Francesco; Mereta, Federico; D'Aria, Irma; Magliano, Danilo; Liberatori, Monica; Cantù, Daniela; Croce, Davide; Eandi, Simone; Colombo, Giorgio Lorenzo; Ferrante, Fulvio; Salè, Emanuela Omodeo; Marinozzi, Andrea; Lenzi, Daniele; Remiddi, Francesca; Remiddi, Stefano.
Afiliación
  • Bracarda S; President of Italian Society of Uro-Oncology, Department of Medical Oncology, Santa Maria Hospital, Terni, Italy.
  • Iacovelli R; Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
  • Baldazzi V; Department of Medical Oncology, Santa Maria Annunziata Hospital, Florence, Italy.
  • Zucali PA; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Gernone A; Department of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Conti GN; Department of Medical Oncology, Policlinico Universitario Azienda Ospedaliera (A.O), Bari, Italy.
  • Pappagallo G; Italian Society of Uro-Oncology, Bologna, Italy.
  • Brunelli M; Italian Society of Uro-Oncology, Bologna, Italy.
  • Bruzzi P; Pathology Unit, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
  • Fiorini E; Department of Clinical Epidemiology, National Institute for Cancer Research, Istituto Scientifico Tumori (IST), Genoa, Italy.
  • Magenta L; PaLiNUro Association, Milan, Italy.
  • Diomede F; PaLiNUro Association, Milan, Italy.
  • Mereta F; Federazione Associazioni Volontariato in Oncologia (F.A.V.O) Federation, Rome, Italy.
  • D'Aria I; Scientific Journalist, Freelance, Milan, Italy.
  • Magliano D; Journalist, Medikea TV, Rome, Italy.
  • Liberatori M; Journalist, Pharmastar, Milan, Italy.
  • Cantù D; Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
  • Croce D; Italian Association of Physiotherapists, Milan, Italy.
  • Eandi S; Centro di Ricerca sull'Economia e il Management in Sanità e nel Sociale, Libero Istituto Universitario Cattaneo (LIUC) Business School, Castellanza (VA), Turin, Italy.
  • Colombo GL; Social Innovation EcosystEm Development (SEEd) Medica Publishers, Turin, Italy.
  • Ferrante F; Studi Analisi Valutazioni Economiche (SAVE) Institute, Milan, Italy.
  • Salè EO; Department of Diagnostic and Pharmaceutical Assistance, Unità Operativa Complessa (UOC) Pharmacy, Local Health Unit Azienda Sanitaria Locale (ASL) Frosinone, Frosinone, Italy.
  • Marinozzi A; Department Hospital Pharmacy, European Institute of Oncology (IEO), Milan, Italy.
  • Lenzi D; Clinical Pharmacy, Azienda Ospedaliera Universitaria (AOU) Ospedali Riuniti, Ancona, Italy.
  • Remiddi F; Medical Department, Azienda Ospedaliera Università, Siena, Italy.
  • Remiddi S; Medical Writing & Statistics Department, NUME PLUS, Florence, Italy.
Front Oncol ; 13: 1186103, 2023.
Article en En | MEDLINE | ID: mdl-37576880
ABSTRACT

Introduction:

Advanced urothelial carcinoma remains aggressive and very hard to cure, while new treatments will pose a challenge for clinicians and healthcare funding policymakers alike. The U-CHANGE Project aimed to redesign the current model of care for advanced urothelial carcinoma patients to identify limitations ("as is" scenario) and recommend future actions ("to be" scenario).

Methods:

Twenty-three subject-matter experts, divided into three groups, analyzed the two scenarios as part of a multidimensional consensus process, developing statements for specific domains of the disease, and a simplified Delphi methodology was used to establish consensus among the experts.

Results:

Recommended actions included increasing awareness of the disease, increased training of healthcare professionals, improvement of screening strategies and care pathways, increased support for patients and caregivers and relevant recommendations from molecular tumor boards when comprehensive genomic profiling has to be provided for appropriate patient selection to ad hoc targeted therapies.

Discussion:

While the innovative new targeted agents have the potential to significantly alter the clinical approach to this highly aggressive disease, the U-CHANGE Project experience shows that the use of these new agents will require a radical shift in the entire model of care, implementing sustainable changes which anticipate the benefits of future treatments, capable of targeting the right patient with the right agent at different stages of the disease.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Italia